By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Bringing to commercialization women’s reproductive health products — starting with a novel contraceptive.
Daré Bioscience is a public company focusing on women’s reproductive health and developing Ovaprene, a novel, vaginally inserted contraceptive ring about to enter clinical trials. Ovaprene is designed to prevent pregnancy by impeding sperm motility with slow-release of ascorbic acid and the iron compound ferrous gluconate from the ring’s permeable mesh. Ovaprene is the first clinical candidate of Daré, which aims to be a global player in developing products that fill the unmet, often overlooked reproductive health needs of women.